Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C
August 15, 2016 (Issue: 1501)
The FDA has approved Epclusa (Gilead), a fixed-dose
combination of sofosbuvir (Sovaldi) and velpatasvir,
a new direct-acting antiviral agent, for oral treatment
of chronic hepatitis C virus (HCV) infection. Epclusa
is the first oral combination...more
- American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. Available at http://hcvguidelines.org. Accessed August 2, 2016.
- Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther 2014; 56:5.
- G Cheng et al. GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J Hepatol 2013; 58 suppl 1:S484. Absctract 1191. Available at: www2.kenes.com. Accessed August 2, 2016.
- EJ Lawitz et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother 2016 Jun 27 (epub).
- JJ Feld et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599.
- GR Foster et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608.
- MP Curry et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373:2618.
- D Wyles et al. Sofosbuvir/velpatasvir in HIV-HCV co-infected patients. Available at: http://slides.hcvonline.org. Accessed August 2, 2016.
- In brief: Severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther 2015; 57:58.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2016; 58:e46.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C
Article code: 1501b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
